Prospective Cohort Study for PCOS Patients in Clinical Reproductive Medicine Management System/Electronic Medical Record Cohort Database (CCRM/EMRCD)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Health Related
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Enrollment
- 10000
- Locations
- 1
- Primary Endpoint
- Level of serum FSH (Follicle stimulating hormone)
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
The Prospective Cohort Study for PCOS Patients was set up to investigate the short- and long-term health consequences in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, China.
Detailed Description
Polycystic ovary syndrome (PCOS) affects 8-13% of women. It is a multifaceted condition characterized by chronic anovulation and excess ovarian activity. Since last decade, Clinical Reproductive Medicine Management System/Electronic Medical Record Cohort Database (CCRM/EMRCD) has been used in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, and Henan Province Key Laboratory for Reproduction and Genetics. Information of patients (POI, PCOS, Endometriosis, azoospermia, ect) were recorded comprehensively. The current project plans to recruit PCOS participants in our center. Biological samples, questionnaires and short/long term health data will be collected. The study is aimed to provide evidence for PCOS prognosis.
Investigators
Yingpu Sun
Director of Reproductive Medical Center
The First Affiliated Hospital of Zhengzhou University
Eligibility Criteria
Inclusion Criteria
- •PCOS patients diagnosed with The Rotterdam diagnostic criteria.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Level of serum FSH (Follicle stimulating hormone)
Time Frame: From date of inclusion, assessed by each 12 month, up to 40 years
mIU/mL
Level of serum LH (Luteinizing hormone)
Time Frame: From date of inclusion, assessed by each 12 month, up to 40 years
mIU/mL
Level of T (Testosterone)
Time Frame: From date of inclusion, assessed by each 12 month, up to 40 years
ng/ml
Secondary Outcomes
- Body Weight(From date of inclusion, assessed by each 12 month, up to 40 years)
- Height(From date of inclusion, assessed by each 12 month, up to 40 years)